Related Experiment Video
Updated: Feb 10, 2026
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
15.2K
Personalized cancer therapy for soft tissue sarcomas: progress and pitfalls
Ola Myklebost1,2,3,4
1Institute for Cancer Research, Oslo University Hospital, Norwegian Radium Hospital, PO Box 4950 Nydalen, 0424 Oslo, Norway.
Personalized Medicine
|May 12, 2018
Summary
Precise sarcoma diagnosis is improving, but many subgroups limit commercial interest. Repurposed drugs and new sequencing offer hope for targeted therapies, though clinical benefit documentation remains challenging.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Sarcoma classification has improved due to precise differential diagnosis, defining most subgroups.
- Despite advances, numerous sarcoma subgroups fragment research opportunities and diminish commercial interest in developing targeted therapies.
- Gastrointestinal stromal tumors exemplify successful drug repurposing, with a leukemia drug showing efficacy.
Purpose of the Study:
- To explore the challenges and opportunities in developing targeted therapies for sarcoma subgroups.
- To highlight the potential of novel sequencing technologies and drug repurposing in sarcoma treatment.
- To emphasize the need for rigorous clinical validation and international collaboration for novel sarcoma therapies.
Main Methods:
- Review of current diagnostic and molecular understanding of sarcoma subgroups.
- Analysis of successful drug repurposing cases, exemplified by gastrointestinal stromal tumors.
- Discussion of the impact of new sequencing technologies on molecular stratification and targeted therapy development.
Main Results:
- Increasing molecular understanding and diagnostic techniques refine sarcoma subgroup definitions.
- Drug repurposing, as seen in gastrointestinal stromal tumors, offers a viable strategy for targeted treatment.
- New sequencing technologies promise improved molecular stratification for personalized therapies.
Conclusions:
- Fragmented sarcoma subgroups present challenges for commercial development but offer opportunities for targeted strategies.
- Repurposed drugs and advanced sequencing technologies hold promise for addressing unmet therapeutic needs in specific sarcoma patient populations.
- Demonstrating clinical benefit requires systematic research, robust data, and international collaboration.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
01:03Rous Sarcoma Virus (RSV) and Cancer
6.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.4K
02:49Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
03:03mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K